BR3005

BR3005 is a fixed-dose combination small molecule drug developed by Boryung for the treatment of type 2 diabetes mellitus. It is being evaluated in clinical trials to compare its pharmacokinetics and safety profile against the co-administration of its individual components (referred to as BR3005-1 and BR3005-2) in healthy adult volunteers under both fasting and fed conditions. The specific active ingredients and mechanisms of action for this combination have not been publicly disclosed as of June 2025. The drug has completed Phase 1 clinical trials in South Korea with no reported approvals or known adverse events[1][2][3][4].